India revised the policy condition governing import of Sulphadiazine active pharmaceutical ingredient (API) recently by imposing a minimum import price (MIP). The import of Sulphadiazine API having a ...
NEW DELHI: In a major move towards ensuring drug security, India's import dependence for raw material to manufacture essential medicines is likely to reduce by 25% by around 2024, a top official said.
On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results